DGAP-News

Vita 34 AG: Increase in Profitability in Q1 Confirms Positive Growth Outlook 2014

DGAP-News: Vita 34 AG / Key word(s): Quarter Results
Vita 34 AG: Increase in Profitability in Q1 Confirms Positive Growth
Outlook 2014

24.04.2014 / 07:35

---------------------------------------------------------------------

Vita 34 AG: Increase in Profitability in Q1 Confirms Positive Growth
Outlook 2014

- Sum of operating income increased to EUR 3.5 million

- Earnings before interest, taxes, depreciation and amortization (EBITDA)
up 72 percent in annual comparison; strong EBITDA margin of 18.3
percent

- Earnings before interest and taxes, (EBIT) rose to EUR 0.3 million.

- Positive outlook for 2014: Introduction of umbilical cord tissue
storage throughout Germany and in international markets offers
potential for revenues and profits

Leipzig, 24 April 2014 - Vita 34 AG (WKN A0BL84), a pioneer in the storage
of stem cells from umbilical cord blood and tissue, and a specialist in
cryo-preservation, published its financial figures for the first three
months of fiscal year 2014 today. The company reported a positive start in
the current fiscal year. Vita 34 is continuing the prior year's positive
trend with an increased sum of operating profits, significantly higher
EBITDA and a positive result for the period.

In the first three months of 2014 the sum of operating profits was EUR 3.5
million, following EUR 3.3 million in the reference time period in 2013.
Among other things, the Biotechnology business segment that had been
expanded in 2013 contributed to the income from research and development
activities, as well as to a positive trend in the financial situation.
Revenues were stable EUR 3.2 million (Q1 2013: EUR 3.2 million). In
addition, the number of new storages of umbilical cord blood and tissue of
1,659 storages was at the prior year's level (Q1 2013: 1,614 new storages).

At the same time, Vita 34 was successful in increasing profitability. Apart
from the Biotechnology business segment, the optimization measures
consistently implemented in fiscal year 2013 contributed to this, and also
demonstrated an effect in the reporting period. For example, the selling
expenses decreased in the first quarter of 2014 to EUR 1.1 million
following EUR 1.2 million in the prior year's quarter. The earnings before
interest, taxes, depreciation and amortization (EBITDA) were increased in
the reporting period to EUR 0.6 million (Q1 2013: EUR 0.3 million).
Measured against revenues this is equivalent to a high EBITDA margin of
18.3 percent. The operating profit (EBIT) improved also and was EUR 0.3